[{"id":"a22bdba7-a048-4ead-8b32-f496954c7c9d","acronym":"","url":"https://clinicaltrials.gov/study/NCT02111850","created_at":"2021-01-18T09:45:59.926Z","updated_at":"2024-07-02T16:36:14.557Z","phase":"Phase 1/2","brief_title":"T Cell Receptor Immunotherapy Targeting MAGE-A3 for Patients With Metastatic Cancer Who Are HLA-DP0401 Positive","source_id_and_acronym":"NCT02111850","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" CD4 • GAPDH • MAGEA3","pipe":"","alterations":" ","tags":["CD4 • GAPDH • MAGEA3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • fludarabine IV • Proleukin (aldesleukin) • MAGE A3 TCR • cyclophosphamide intravenous"],"overall_status":"Completed","enrollment":" Enrollment 21","initiation":"Initiation: 02/07/2014","start_date":" 02/07/2014","primary_txt":" Primary completion: 03/24/2021","primary_completion_date":" 03/24/2021","study_txt":" Completion: 03/24/2021","study_completion_date":" 03/24/2021","last_update_posted":"2022-03-29"}]